At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Pre-Mkt 02-06 06:12:57 EST
1.18
-0.09
-7.09%
High1.40Low1.17Vol6.93M
Open1.33D1 Closing1.27Amplitude17.72%
Mkt Cap493.24MTradable Cap282.02MTotal Shares418.00M
T/O8.75MT/O Rate2.90%Tradable Shares239.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
TIPRANKS  ·  02-03
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing
BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology
Reuters  ·  01-30
BUZZ-U.S. STOCKS ON THE MOVE-ResMed, Stryker, ALX Oncology
BRIEF-Lexicon Announces Pricing Of Approximately $94.6 Million Public Offering At $1.30 Per Share
Reuters  ·  01-30
BRIEF-Lexicon Announces Pricing Of Approximately $94.6 Million Public Offering At $1.30 Per Share
Lexicon Pharmaceuticals Inc - Shares Offered at $1.30 per Share
THOMSON REUTERS  ·  01-30
Lexicon Pharmaceuticals Inc - Shares Offered at $1.30 per Share
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
THOMSON REUTERS  ·  01-30
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
BUZZ-Lexicon Pharma slides after stock offering unveil
Reuters  ·  01-30
BUZZ-Lexicon Pharma slides after stock offering unveil
Lexicon announces common stock offering, no amount given
TIPRANKS  ·  01-30
Lexicon announces common stock offering, no amount given
Lexicon Announces Proposed Public Offering of Common Stock
THOMSON REUTERS  ·  01-30
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
GlobeNewswire  ·  01-23
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Reuters  ·  01-21
BUZZ-U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous
Reuters  ·  01-21
BUZZ-U.S. STOCKS ON THE MOVE-Teledyne, Arm Holdings, Nathan’s Famous
BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug
Reuters  ·  01-21
BUZZ-Lexicon rises as FDA clears late‑stage test of diabetic nerve‑pain drug
Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain
Reuters  ·  01-21
Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Neuropathic Pain
Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development
THOMSON REUTERS  ·  01-21
Lexicon Pharmaceuticals Inc - FDA Raised No Objections to Advancement of Pilavapadin Into Phase 3 Development
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
THOMSON REUTERS  ·  01-21
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting With FDA for Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target
TIPRANKS  ·  01-21
Lexicon Pharmaceuticals: Global INPEFA Expansion and Late-Stage Pipeline Catalysts Support Buy Rating and $4 Target
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)
TIPRANKS  ·  01-16
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)
Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference
Reuters  ·  01-12
Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference
THOMSON REUTERS  ·  01-12
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference
Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments
Reuters  ·  01-09
Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--